BiotechTube

GSK3050002 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colitis, Ulcerative

Conditions

Colitis, Ulcerative

Trial Timeline

Jan 10, 2014 → Feb 23, 2015

NCT ID
NCT01984047

About GSK3050002 + Placebo

GSK3050002 + Placebo is a phase 1 stage product being developed by Eisai for Colitis, Ulcerative. The current trial status is completed. This product is registered under clinical trial identifier NCT01984047. Target conditions include Colitis, Ulcerative.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01984047Phase 1Completed

Competing Products

20 competing products in Colitis, Ulcerative

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
77
MirikizumabEli LillyPhase 2
52
Azathioprine + PlaceboCelltrionApproved
85
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
TacrolimusAstellas PharmaPhase 3
77
tacrolimus + PlaceboAstellas PharmaPhase 3
77
Filgotinib MaleateEisaiApproved
85
AJM300 + PlaceboEisaiPhase 3
77
adalimumab + placeboEisaiPhase 3
77
E6007 + PlaceboEisaiPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 1
33
Arm1 + Arm 2Zydus LifesciencesPhase 2
52
Mirikizumab + MirikizumabEli LillyPhase 3
77
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 2
52
Mirikizumab + PlaceboEli LillyPhase 2
52
LY4268989 + PlaceboEli LillyPhase 2
52
Eltrekibart + Mirikizumab + PlaceboEli LillyPhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85